In addition, a phase I randomized study of MAGE-12 peptide vaccine has been conducted in patients with refractory uterine sarcoma expressing MAGE-12 antigen (NCT00020267; http://clinicaltrials.gov/ct2/show/NCT00020267?term=uterine+sarcoma&rank=3). The gene discussed is MAGEA12; the disease is sarcoma.